AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation
AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.
TL;DR
- AstraZeneca is investing $15 billion in China through 2030 to expand manufacturing and R&D, aiming to bring Chinese innovation to the global market.
- The company is partnering with Hong Kong-listed CSPC Pharmaceuticals on eight preclinical and early-stage obesity programs, with potential payments up to $18.5 billion.
- AstraZeneca's shares are set to list on the New York Stock Exchange, following a $50 billion U.S. investment announcement.
- The pharmaceutical industry is increasingly seeking innovation from China to compensate for blockbuster drugs losing patent protection.
- China's biopharma sector is emerging as a leader in early-stage development due to factors like efficient clinical trial infrastructure and returning scientists.
- Licensing deals between major pharmaceutical companies and Chinese biotechs have sharply increased in recent years.